- Postdoc - St. Jude Children's Research Hospital, Memphis, TN
- Ph.D. - Université Laval, Quebec City, Quebec, Canada
- B.S. - Université Laval, Quebec City, Quebec, Canada
Education & Training
Review based on the experience acquired through my work using CRISPR/Cas9 technology:
Pelletier S, Gingras S, Green DR. 2015. Mouse genome engineering via CRISPR-Cas9 for study of immune function. Immunity 42(1):18-27.
First publication describing a genetically engineered mice using CRISPR/Cas9 technology of my design:
Martinez J, Malireddi RK, Lu Q, Cunha LD, Pelletier S, Gingras S, Orchard R, Guan JL, Tan H, Peng J, Kanneganti TD, Virgin HW, Green DR. 2015. Molecular characterization of LC3-associated phagocytosis reveals distinct roles for Rubicon, NOX2 and autophagy proteins. Nature cell biology 17(7):893-906.
Genetically engineered mouse models to uncover the mechanistic function of new genes.
Gingras S, Earls LR, Howell S, Smeyne RJ, Zakharenko SS, Pelletier S. 2015. SCYL2 Protects CA3 Pyramidal Neurons from Excitotoxicity during Functional Maturation of the Mouse Hippocampus. The Journal of neuroscience 35(29):10510-22.
Pelletier S, Gingras S, Howell S, Vogel P, Ihle JN. 2012. An early onset progressive motor neuron disorder in Scyl1-deficient mice is associated with mislocalization of TDP-43. The Journal of neuroscience 32(47):16560-73.
Gingras S, Pelletier S, Boyd K, Ihle JN. 2007. Characterization of a family of novel cysteine- serine-rich nuclear proteins (CSRNP). PloS one. 2007; 2(8):e808.
I'm responsible for the scientific direction and day-to-day management of an Innovative Technologies Development Core Facility. This facility will have several purposes and goals, chiefly, to: a) develop novel genetically engineered animal models that will permit powerful genetic and phenotypic modulation; b) enable and implement CRISPR/Cas9 technology for genome modification of both organisms and cell lines; c) provide design and production services to the users of this Core facility, including faculty and staff, in support of their projects to engineer CRISPR/Cas9 modification of organisms and cells.
For the past 15 years I have been creating and using complex genetically engineered mouse models to uncover the mechanistic function of new genes. I have extensive expertise with every step required to generate a genetically engineered mouse either using conventional techniques in ES cells or more recently with the CRISPR/Cas9 system. Starting in May 2013, I have started using CRISPR/Cas9 system to create genetically engineered mouse model, including knockouts, conditional knockouts, knockins, and point mutations; I have generated more than 25 different mouse lines so far.